UKCTOCS Longitudinal Women's Cohort (UKLWC)
Samples & data for following diseases: Cerebrovascular accident ,Dementia ,Fit and well, Heart disease ,Malignant neoplasm of endometrium of corpus uteri ),Malignant tumour of breast,Malignant colon tumour, and others. Full list in Description… This is the bioresource resulting from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), one of the world's largest randomised controlled trials. Between 2001-2005 1.2 million women aged 50-74 years were invited from the general population and 202,638 post-menopausal were randomised (2:1:1) to routine care, or annual CA125 blood testing (7-11 rounds) or ultrasound to evaluate the impact of ovarian cancer screening on disease mortality. All participants provided a serum sample at recruitment with 50,262 providing further longitudinal annual samples (median of 9 samples). Women were free of any active malignancy at enrolment (2001-2005). During the follow-up period of >15 years to-date a proportion of those have subsequently developed a number of different diseases. Available comprehensive electronic health record linkage of the cohort's participants (including Hospital Episode Statistics (HES); ONS (Cancer registry, Death Certificates); National Cancer Intelligence Network (NCIN); and Myocardial Ischaemia National Audit Project (MINAP) allows exploiting clinical phenotyping and diseases diagnoses made during routine healthcare in the NHS. Women were also sent postal questionnaires. Secondary studies have to date generated additional data on symptoms, menopause and its management and further details of individual cancers. The biobank contains >540,000 high-quality serum samples (10 x 500μL aliquots in straws), composed of baseline (from >189,000 women) and a unique longitudinal set of >350,000 annual serial samples (median 9) (from approximately 50,200 women). Samples have already been validated for multi-omics analysis with academic and commercial collaborators in nested case/controls sets used for genotyping, proteomics (including SWATH technology), methylation, NMR metabolomics, autoantibody profiling, ELISA-based assays, lipidomics and miRNA. We provide access to collection of samples and data across the following diseases: • Cerebrovascular accident (disorder) • Dementia (disorder) • Fit and well • Heart disease (disorder) • Malignant neoplasm of endometrium of corpus uteri (disorder) • Malignant tumour of breast, Malignant tumour of colon, Malignant tumour of lung, Malignant tumour of ovary • Malignant tumour of pancreas All data is stored in the IG Toolkit-compliant and ISO 27001:2013-certified UCL Data Safe Haven. All samples from the biobank have been collected using a standardised protocol and stored in liquid nitrogen at HTA licensed facilities at UK Biocentre, Oxford, UK.
Webpage:
https://www.healthdatagateway.org/dataset/cb7370a6-a1b0-4473-a32f-ec85ec0155a5
Licence:
Name: HDR UK Innovation Gateway Access
Tags:
dementia malignant neoplasm of endometrium of corpus uteri ) uklwc malignant colon tumour ukctocs women's heart disease cerebrovascular accident malignant tumour of breast longitudinal cohort fit and well
Need help integrating and/or managing biomedical data?